MSD's anti-PD-1 therapy Keytruda did not meet its co-primary endpoints in the Phase III KEYNOTE-240 trial involving patients with liver cancer.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.